Skip to main content

6 Result(s)

within AB Mehta Remove this filter

and

  1. No Access

    Article

    Heterogeneity of VH–JH gene rearrangement patterns: an insight into the biology of B cell precursor ALL

    Oligoclonal B cell proliferation, as defined by the presence of more than one leukemic clone, has been detected in approximately 20% to 30% of patients with acute lymphoblastic leukemia (ALL) using PCR or Sout...

    I Moreira, M Papaioannou, FY Mortuza, P Gameiro, GL Palmisano, CJ Harrison… in Leukemia (2001)

  2. No Access

    Article

    Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities

    Forty of the 550 patients (7%) entered to the 11q23 Workshop had secondary (s) acute lymphoblastic leukemia (nine cases), s-acute myeloid leukemia (25 cases, predominantly of FAB type M5), s-acute leukemia uns...

    LM Secker-Walker, AV Moorman, BJ Bain, AB Mehta in Leukemia (1998)

  3. No Access

    Article

    Myelodysplastic syndromes associated with 11q23 abnormalities

    Most hematological neoplasms associated with 11q23 chromosomal rearrangement have been cases of acute lymphoblastic or acute myeloid leukemia. Although cases of myelodysplastic syndrome (MDS) are a minority, t...

    BJ Bain, AV Moorman, B Johansson, AB Mehta, LM Secker-Walker in Leukemia (1998)

  4. No Access

    Article

    Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response

    Immunoglobulin heavy chain gene (IgH gene) rearrangements are found in the majority of patients with B lineage acute lymphoblastic leukaemia (ALL). Two hundred and three bone marrow samples from 54 patients (3...

    L Foroni, LA Coyle, M Papaioannou, JC Yaxley, MF Cole Sinclair, JS Chim… in Leukemia (1997)

  5. No Access

    Article

    Fludarabine phosphate for the treatment of low grade lymphoid malignancy

    Thirty-four patients with previously treated, advanced, low grade NHL were treated with Fludarabine, a deamination-resistant analogue of adenosine arabinoside, at a dose of 25 mg m-2 intravenously, daily for 5...

    JS Whelan, CL Davis, S Rule, M Ranson, OP Smith, AB Mehta… in British Journal of Cancer (1991)

  6. No Access

    Article

    A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease

    Biological response modifiers such as interleukin 2 (IL2) may be most effective in the setting of minimal residual disease. In a phase I-II clinical trial, IL2 was administered to 10 patients in remission of a...

    DJ Gottlieb, MK Brenner, HE Heslop, ACM Bianchi… in British Journal of Cancer (1989)